R&D | January 02, 2025
Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Subscribe To Our Newsletter & Stay Updated
